Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifieque
InventorsFrederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque
Life of this patent
Estimating the term…
Abstract
The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
Claims26
An immunogenic composition comprising (i) a recombinant measles virus expressing a heterologous amino acid sequence, or a recombinant measles virus expression vector, and (ii) an acceptable vehicle, wherein said virus or vector comprises a sequence comprising:
- A) a nucleotide sequence encoding the full length antigenomic (+)RNA strand of a measles virus vaccine strain;
- B) a T7 promoter sequence comprising a GGG motif at its 3′ end, operably linked to the nucleotide sequence of A;
- C) a hammerhead ribozyme sequence located adjacent to the GGG motif at one end and adjacent to the first nucleotide of the nucleotide sequence encoding the full length anti-genomic (+)RNA strand of the measles virus strain at the other end;
- D) a T7 terminator sequence operably linked to the nucleotide sequence of A;
- E) the sequence of a hepatitis delta virus ribozyme located adjacent to the last nucleotide of the nucleotide sequence encoding the full length anti-genomic (+)RNA strand of the measles virus;
- and
- F) a heterologous coding sequence encoding a heterologous amino acid sequence comprising an antigen of a heterologous RNA virus selected from a retrovirus and a flavivirus.
Dependencies are inferred from the claim text.